|
Market Closed -
Other stock markets
|
Pre-market 14:29:25 | |||
| 19.93 USD | +0.35% |
|
19.78 | -0.78% |
| 05-18 | Elanco Animal Health Launches Canine Dermatitis Drug Befrena | MT |
| 05-18 | Elanco Animal Health Incorporated Launches Befrena, New Anti-IL-31 Monoclonal Antibody | CI |
| Capitalization | 9.95B 8.55B 7.83B 7.43B 13.68B 959B 13.92B 93.66B 36.3B 454B 37.36B 36.57B 1,581B | P/E ratio 2026 * |
234x | P/E ratio 2027 * | 77.6x |
|---|---|---|---|---|---|
| Enterprise value | 12.93B 11.11B 10.17B 9.65B 17.78B 1,246B 18.08B 122B 47.15B 589B 48.53B 47.5B 2,054B | EV / Sales 2026 * |
2.56x | EV / Sales 2027 * | 2.33x |
| Free-Float |
98.81% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Elanco Animal Health Incorporated
| 1 day | -0.63% | ||
| 1 week | -8.24% | ||
| Current month | -10.91% | ||
| 1 month | -15.84% | ||
| 3 months | -19.57% | ||
| 6 months | -6.83% | ||
| Current year | -11.93% |
| 1 week | 19.68 |  | 22.17 |
| 1 month | 19.68 | | 26.29 |
| Current year | 19.68 | | 27.72 |
| 1 year | 12.4 | | 27.72 |
| 3 years | 7.88 | | 27.72 |
| 5 years | 7.88 | | 37.49 |
| 10 years | 7.88 | | 37.61 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeffrey Simmons
CEO | Chief Executive Officer | 58 | 30/06/2018 |
| Director of Finance/CFO | 50 | 06/07/2025 | |
Shabbir Simjee
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Simmons
BRD | Director/Board Member | 58 | 30/06/2018 |
R. Hoover
CHM | Chairman | 79 | 30/04/2018 |
Kapila Anand
BRD | Director/Board Member | 72 | 31/08/2018 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +4.97% | 0.35% | 27 M€ | |
| -.--% | 0.33% | 2 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.35% | -8.24% | +54.26% | +129.08% | 9.95B | |
| +4.72% | +1.37% | -52.33% | -56.75% | 32.58B | |
| -1.64% | -3.46% | +20.97% | +47.78% | 5.43B | |
| +2.17% | +2.17% | +14.98% | +14.98% | 3.37B | |
| -5.00% | -6.92% | +99.86% | +34.18% | 2.29B | |
| 0.00% | -0.50% | -26.92% | -8.11% | 1.67B | |
| -0.55% | -5.89% | +42.42% | +146.43% | 1.39B | |
| +0.47% | -4.70% | -28.42% | -10.16% | 1.15B | |
| -1.53% | -5.21% | +0.57% | -45.08% | 1.06B | |
| -2.24% | -4.26% | -17.35% | -39.74% | 981M | |
| Average | -0.75% | -3.88% | +10.80% | +21.26% | 5.99B | |
| Weighted average by Cap. | +0.38% | -1.91% | -13.49% | -1.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.05B 4.34B 3.97B 3.77B 6.94B 486B 7.06B 47.52B 18.42B 230B 18.95B 18.55B 802B | 5.32B 4.57B 4.18B 3.97B 7.31B 512B 7.44B 50.05B 19.4B 242B 19.96B 19.54B 845B |
| Net income | 45.06M 38.72M 35.42M 33.64M 61.94M 4.34B 63M 424M 164M 2.05B 169M 166M 7.16B | 126M 108M 99.05M 94.07M 173M 12.14B 176M 1.19B 459M 5.74B 473M 463M 20.02B |
| Net Debt | 2.98B 2.56B 2.34B 2.22B 4.09B 287B 4.16B 28.01B 10.85B 136B 11.17B 10.93B 473B | 2.43B 2.09B 1.91B 1.82B 3.34B 234B 3.4B 22.89B 8.87B 111B 9.13B 8.94B 386B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/05/26 | 19.93 $ | +0.35% | 7,877,363 |
| 15/05/26 | 19.86 $ | -8.23% | 7,849,467 |
| 14/05/26 | 21.64 $ | -0.73% | 4,739,202 |
| 13/05/26 | 21.80 $ | +1.73% | 8,468,820 |
| 12/05/26 | 21.43 $ | -1.34% | 10,857,025 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ELAN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition